Second Rotating Therapy Machine Launched, Bringing Total to Three Including One Fixed Unit
Expansion of Treatment Eligibility to Focus on Intractable Cancers Difficult to Operate On
Capable of Treating Up to 10,800 Patients Annually

On August 19, Yonsei Cancer Hospital announced that it will expand the types of cancer eligible for heavy ion therapy to include head and neck cancer, sarcoma, and recurrent rectal cancer.


Yonsei Cancer Hospital began heavy ion therapy in 2023 with prostate cancer, later broadening treatment indications to pancreatic, liver, and lung cancers. This latest expansion extends eligibility to cancers that are difficult to operate on or are highly resistant to conventional radiotherapy.

Geum Woongseop, Head of the Particle Therapy Center at Yonsei Cancer Hospital (left), and other medical staff are preparing for particle therapy. Severance Hospital

Geum Woongseop, Head of the Particle Therapy Center at Yonsei Cancer Hospital (left), and other medical staff are preparing for particle therapy. Severance Hospital

View original image

The second rotating heavy ion therapy machine will also be put into full operation. As a result, the hospital will operate a total of three heavy ion therapy devices: one fixed and two rotating units. Yonsei Cancer Hospital is the first in the world to operate all three types of machines. These facilities can treat approximately 40 patients per day and up to 10,800 patients annually.


For head and neck cancers, critical organs such as the brain, spinal cord, optic nerve, and major blood vessels and nerves are closely clustered, making it vital to treat the tumor while protecting normal tissues. Heavy ion therapy leverages the 'Bragg peak' effect to concentrate energy at a specific depth, reducing radiation exposure to nearby healthy tissues. Target cases include inoperable non-squamous cell carcinomas, such as those occurring in the paranasal sinus, skull base, and salivary glands.


According to a Japanese multicenter study (J-CROS), the five-year local control rates after heavy ion therapy for patients with inoperable head and neck cancer were reported as 68% for adenoid cystic carcinoma and 84% for mucosal malignant melanoma.


When sarcomas develop in the spine, pelvis, sacrum, or skull base—areas difficult to access surgically—complete resection is often not possible, and the tumors may be highly resistant to conventional radiotherapy. Japanese studies have reported a five-year local control rate of 74% and a five-year survival rate of 73% after heavy ion therapy for unresectable osteosarcoma.


Recurrent rectal cancer is often located near major pelvic organs, which can necessitate large surgical resections, and patients who have previously received radiotherapy are at greater risk of damage to normal tissues upon re-irradiation. In the J-CROS study, the three-year local control rate after heavy ion therapy for inoperable recurrent rectal cancer was 93%, the five-year rate was 88%, and the three-year survival rate was 73%.


Geum Woongseop, Director of the Heavy Ion Therapy Center at Yonsei Cancer Hospital, stated, "For difficult-to-treat tumors in areas where multiple vital organs are clustered, or tumors resistant to conventional treatments, it is crucial to enhance treatment efficacy while minimizing damage to normal tissues. By operating the second rotating heavy ion therapy machine, we aim to further expand personalized treatment for each patient."



Lee Sanggil, Director of Yonsei Cancer Hospital, commented, "Heavy ion therapy should not be seen as a last-resort treatment, but rather must be actively considered depending on the patient's condition and the timing of treatment. We will apply standard therapies such as surgery, chemotherapy, and radiation, along with heavy ion therapy, tailored to each patient's needs."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing